Business Context and Reporting Period
Company: ZIMMER BIOMET HOLDINGS, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: April 28, 2016
Reporting Period: Quarter ended March 31, 2016
Context: The filing reports results of operations for the first quarter of 2016. The company notes that the earnings release (Exhibit 99.1) contains non-GAAP financial measures adjusted for the Biomet merger, inventory step-up, restructuring, and currency fluctuations.
Key Financial Metrics
The provided text serves as a cover report referencing an attached earnings release (Exhibit 99.1). Consequently, specific numerical values for the following metrics are not present in this document:
- Revenue: Not stated in text (referenced as reported, pro forma, and adjusted pro forma constant currency).
- Profit: Not stated in text (referenced as adjusted net earnings and adjusted diluted EPS).
- Cash Flow, Margins, Debt, Liquidity: Not stated in text.
The filing defines "Adjusted net earnings" and "Adjusted diluted EPS" as excluding inventory step-up, manufacturing charges, claims, special items, intangible asset amortization, and merger-related financing expenses.
Material Changes and Adjustments
The filing highlights several adjustments made to financial data to facilitate period-to-period comparisons:
- Pro Forma Adjustments: Prior year revenue is adjusted to include Biomet revenue on a GAAP basis.
- Divestiture Remedies: Adjusted pro forma revenue excludes the impact of previously announced divestiture remedies.
- Currency Impact: Adjusted pro forma constant currency revenue excludes foreign exchange rate changes.
- Special Items: Exclusions include business combination costs, global restructuring, quality initiatives, employee termination benefits, contract terminations, and asset impairments.
Guidance, Outlook, and Risks
Management Commentary: Management utilizes non-GAAP measures internally to evaluate performance, identify operating trends masked by special items, and for incentive compensation metrics. The company asserts these measures provide transparency and meaningful comparisons.
Risks and Contingencies: The filing explicitly states that non-GAAP measures may not be comparable to similar measures reported by other companies and should not be viewed as a substitute for GAAP measures. The information is furnished pursuant to Item 2.02 and is not deemed "filed" with the SEC for incorporation by reference.
Guidance: The text mentions "projected adjusted diluted EPS" is included in the attached earnings release, but no specific forward-looking numbers are provided in this summary text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, earnings, and cash flow figures, as they are not included in the 8-K text.
- Verify the reconciliation tables in the earnings release to understand the magnitude of adjustments between GAAP and non-GAAP measures.
- Confirm the specific impact of foreign currency exchange rates on reported sales growth.
- Examine the details of special items (restructuring, impairments, merger costs) excluded from adjusted earnings.
- Check for any updated divestiture remedy impacts on pro forma revenue calculations.